Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.

Lingvay I, Hansen T, Macura S, Marre M, Nauck MA, de la Rosa R, Woo V, Yildirim E, Wilding J

BMJ open diabetes research & care1 Oct 2020Cited by 39 (Europe PMC)

PMID33115821PMCIDPMC7594204DOI10.1136/bmjdrc-2020-001706PepBankPUB-33115821

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyMechanism
In diabetes patients, nausea/vomiting explained little of semaglutide's greater weight loss versus exenatide in SUSTAIN 3.
In plain wordsIn people with diabetes, nausea and vomiting explained little of semaglutide's greater weight loss compared with exenatide.
Peptide
Semaglutide
Outcome
DecreaseNausea/vomiting-mediated weight loss difference versus exenatide
Study
n: not reported in source
Comparator
Exenatide extended release
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 56 weeksAs given in this study (human).
Measurements
Mediated weight loss difference
0.05 kg
baseline to week 12, SUSTAIN 3
Mediated weight loss difference
0.09 kg
baseline to end of treatment, SUSTAIN 3
Total weight loss difference
3.78 kg
end of treatment, SUSTAIN 3
Source sentences
Summary
From baseline to week 12 or EOT, the nausea/vomiting-mediated difference in WL was, respectively: 0.05 or 0.09 kg of 3.78 kg at EOT (SUSTAIN 3);
3 context sentences(design, population, supporting numbers)
Summary · context
Semaglutide demonstrated superior glycated hemoglobin and body weight (BW) reductions versus other GLP-1RAs in SUSTAIN 3 (versus exenatide extended release 2.0 mg), SUSTAIN 7 (versus dulaglutide) and SUSTAIN 10 (liraglutide 1.2 mg).
Summary · context
Subjects within trials were subdivided into those who reported (yes/no) nausea/vomiting or any other GI AE.
Summary · context
A mediation analysis separated WL into direct or indirect (mediated by GI AEs) effects.
Report a problemFND-3311582101
02HumanObservational studyMechanism
In diabetes patients, nausea/vomiting explained little of semaglutide's greater weight loss versus dulaglutide in the low-dose comparison.
In plain wordsIn people with diabetes, nausea and vomiting explained little of semaglutide's greater weight loss than dulaglutide in the low-dose comparison.
Peptide
Semaglutide
Outcome
DecreaseNausea/vomiting-mediated weight loss difference, low-dose SUSTAIN 7
Study
n: not reported in source
Comparator
Dulaglutide, low-dose comparison
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 40 weeksAs given in this study (human).
Measurements
Mediated weight loss difference
0.06 kg
baseline to week 12, low-dose SUSTAIN 7
Mediated weight loss difference
0.03 kg
baseline to end of treatment, low-dose SUSTAIN 7
Total weight loss difference
2.26 kg
end of treatment, low-dose SUSTAIN 7
Source sentences
Summary
0.06 or 0.03 kg of 2.26 kg at EOT (low-dose comparison) and 0.08 or 0.04 kg of 3.55 kg at EOT (high-dose comparison) (SUSTAIN 7)
4 context sentences(design, population, supporting numbers)
Summary · context
From baseline to week 12 or EOT, the nausea/vomiting-mediated difference in WL was, respectively:
Summary · context
Semaglutide demonstrated superior glycated hemoglobin and body weight (BW) reductions versus other GLP-1RAs in SUSTAIN 3 (versus exenatide extended release 2.0 mg), SUSTAIN 7 (versus dulaglutide) and SUSTAIN 10 (liraglutide 1.2 mg).
Summary · context
Subjects within trials were subdivided into those who reported (yes/no) nausea/vomiting or any other GI AE.
Summary · context
A mediation analysis separated WL into direct or indirect (mediated by GI AEs) effects.
Report a problemFND-3311582102
03HumanObservational studyMechanism
In diabetes patients, nausea/vomiting explained little of semaglutide's greater weight loss versus dulaglutide in the high-dose comparison.
In plain wordsIn people with diabetes, nausea and vomiting explained little of semaglutide's greater weight loss than dulaglutide in the high-dose comparison.
Peptide
Semaglutide
Outcome
DecreaseNausea/vomiting-mediated weight loss difference, high-dose SUSTAIN 7
Study
n: not reported in source
Comparator
Dulaglutide, high-dose comparison
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 40 weeksAs given in this study (human).
Measurements
Mediated weight loss difference
0.08 kg
baseline to week 12, high-dose SUSTAIN 7
Mediated weight loss difference
0.04 kg
baseline to end of treatment, high-dose SUSTAIN 7
Total weight loss difference
3.55 kg
end of treatment, high-dose SUSTAIN 7
Source sentences
Summary
0.06 or 0.03 kg of 2.26 kg at EOT (low-dose comparison) and 0.08 or 0.04 kg of 3.55 kg at EOT (high-dose comparison) (SUSTAIN 7)
4 context sentences(design, population, supporting numbers)
Summary · context
From baseline to week 12 or EOT, the nausea/vomiting-mediated difference in WL was, respectively:
Summary · context
Semaglutide demonstrated superior glycated hemoglobin and body weight (BW) reductions versus other GLP-1RAs in SUSTAIN 3 (versus exenatide extended release 2.0 mg), SUSTAIN 7 (versus dulaglutide) and SUSTAIN 10 (liraglutide 1.2 mg).
Summary · context
Subjects within trials were subdivided into those who reported (yes/no) nausea/vomiting or any other GI AE.
Summary · context
A mediation analysis separated WL into direct or indirect (mediated by GI AEs) effects.
Report a problemFND-3311582103
04HumanObservational studyMechanism
In diabetes patients, nausea/vomiting explained little of semaglutide's greater weight loss versus liraglutide in SUSTAIN 10.
In plain wordsIn people with diabetes, nausea and vomiting explained little of semaglutide's greater weight loss compared with liraglutide.
Peptide
Semaglutide
Outcome
DecreaseNausea/vomiting-mediated weight loss difference versus liraglutide
Study
n: not reported in source
Comparator
Liraglutide 1.2 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Measurements
Mediated weight loss difference
0.05 kg
baseline to week 12, SUSTAIN 10
Mediated weight loss difference
0.09 kg
baseline to end of treatment, SUSTAIN 10
Total weight loss difference
3.82 kg
end of treatment, SUSTAIN 10
Source sentences
Summary
and 0.05 or 0.09 kg of 3.82 kg at EOT (SUSTAIN 10).
4 context sentences(design, population, supporting numbers)
Summary · context
From baseline to week 12 or EOT, the nausea/vomiting-mediated difference in WL was, respectively:
Summary · context
Semaglutide demonstrated superior glycated hemoglobin and body weight (BW) reductions versus other GLP-1RAs in SUSTAIN 3 (versus exenatide extended release 2.0 mg), SUSTAIN 7 (versus dulaglutide) and SUSTAIN 10 (liraglutide 1.2 mg).
Summary · context
Subjects within trials were subdivided into those who reported (yes/no) nausea/vomiting or any other GI AE.
Summary · context
A mediation analysis separated WL into direct or indirect (mediated by GI AEs) effects.
Report a problemFND-3311582106
05HumanObservational studyMechanism
In diabetes patients, liraglutide produced less weight loss than semaglutide, with little difference explained by nausea/vomiting.
In plain wordsIn people with diabetes, liraglutide produced less weight loss than semaglutide; nausea and vomiting explained little of the difference.
Peptide
Liraglutide
Outcome
IncreaseNausea/vomiting-mediated weight loss difference versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg · 30 weeksAs given in this study (human).
Measurements
Mediated weight loss difference
0.05 kg
baseline to week 12, SUSTAIN 10
Mediated weight loss difference
0.09 kg
baseline to end of treatment, SUSTAIN 10
Total weight loss difference
3.82 kg
end of treatment, SUSTAIN 10
Source sentences
Summary
and 0.05 or 0.09 kg of 3.82 kg at EOT (SUSTAIN 10).
4 context sentences(design, population, supporting numbers)
Summary · context
From baseline to week 12 or EOT, the nausea/vomiting-mediated difference in WL was, respectively:
Summary · context
Semaglutide demonstrated superior glycated hemoglobin and body weight (BW) reductions versus other GLP-1RAs in SUSTAIN 3 (versus exenatide extended release 2.0 mg), SUSTAIN 7 (versus dulaglutide) and SUSTAIN 10 (liraglutide 1.2 mg).
Summary · context
Subjects within trials were subdivided into those who reported (yes/no) nausea/vomiting or any other GI AE.
Summary · context
A mediation analysis separated WL into direct or indirect (mediated by GI AEs) effects.
Report a problemFND-3311582107

Studies that did not test the peptide alone2

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyMechanism
In diabetes patients, dulaglutide produced less weight loss than semaglutide, with little difference explained by nausea/vomiting in the low-dose comparison.
In plain wordsIn people with diabetes, dulaglutide produced less weight loss than semaglutide; nausea and vomiting explained little of the low-dose difference.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseNausea/vomiting-mediated weight loss difference, low-dose SUSTAIN 7
Study
n: not reported in source
Comparator
Semaglutide, low-dose comparison
Outcome group
Body weight · Metabolic and weight
Measurements
Mediated weight loss difference
0.06 kg
baseline to week 12, low-dose SUSTAIN 7
Mediated weight loss difference
0.03 kg
baseline to end of treatment, low-dose SUSTAIN 7
Total weight loss difference
2.26 kg
end of treatment, low-dose SUSTAIN 7
Source sentences
Summary
0.06 or 0.03 kg of 2.26 kg at EOT (low-dose comparison) and 0.08 or 0.04 kg of 3.55 kg at EOT (high-dose comparison) (SUSTAIN 7)
4 context sentences(design, population, supporting numbers)
Summary · context
From baseline to week 12 or EOT, the nausea/vomiting-mediated difference in WL was, respectively:
Summary · context
Semaglutide demonstrated superior glycated hemoglobin and body weight (BW) reductions versus other GLP-1RAs in SUSTAIN 3 (versus exenatide extended release 2.0 mg), SUSTAIN 7 (versus dulaglutide) and SUSTAIN 10 (liraglutide 1.2 mg).
Summary · context
Subjects within trials were subdivided into those who reported (yes/no) nausea/vomiting or any other GI AE.
Summary · context
A mediation analysis separated WL into direct or indirect (mediated by GI AEs) effects.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3311582104
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyMechanism
In diabetes patients, dulaglutide produced less weight loss than semaglutide, with little difference explained by nausea/vomiting in the high-dose comparison.
In plain wordsIn people with diabetes, dulaglutide produced less weight loss than semaglutide; nausea and vomiting explained little of the high-dose difference.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseNausea/vomiting-mediated weight loss difference, high-dose SUSTAIN 7
Study
n: not reported in source
Comparator
Semaglutide, high-dose comparison
Outcome group
Body weight · Metabolic and weight
Measurements
Mediated weight loss difference
0.08 kg
baseline to week 12, high-dose SUSTAIN 7
Mediated weight loss difference
0.04 kg
baseline to end of treatment, high-dose SUSTAIN 7
Total weight loss difference
3.55 kg
end of treatment, high-dose SUSTAIN 7
Source sentences
Summary
0.06 or 0.03 kg of 2.26 kg at EOT (low-dose comparison) and 0.08 or 0.04 kg of 3.55 kg at EOT (high-dose comparison) (SUSTAIN 7)
4 context sentences(design, population, supporting numbers)
Summary · context
From baseline to week 12 or EOT, the nausea/vomiting-mediated difference in WL was, respectively:
Summary · context
Semaglutide demonstrated superior glycated hemoglobin and body weight (BW) reductions versus other GLP-1RAs in SUSTAIN 3 (versus exenatide extended release 2.0 mg), SUSTAIN 7 (versus dulaglutide) and SUSTAIN 10 (liraglutide 1.2 mg).
Summary · context
Subjects within trials were subdivided into those who reported (yes/no) nausea/vomiting or any other GI AE.
Summary · context
A mediation analysis separated WL into direct or indirect (mediated by GI AEs) effects.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-3311582105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
22 Oct 2026, 02:26 UTC
Study results updated
Versions 2 to 3
21 Oct 2026, 18:59 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events.

Summary

Results from this study7

Studies that did not test the peptide alone2

Version history

Subjects

Publication types

MeSH terms

Keywords